Investment Analysts’ Recent Ratings Updates for Surgery Partners (SGRY)

Surgery Partners (NASDAQ: SGRY) recently received a number of ratings updates from brokerages and research firms:

• 3/11/2026 – Surgery Partners had its “buy” rating reaffirmed by UBS Group AG.
• 3/11/2026 – Surgery Partners was given a new $21.00 price target by US Capital Advisors.
• 3/5/2026 – Surgery Partners had its price target lowered by TD Cowen from $28.00 to $20.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Surgery Partners had its price target lowered by UBS Group AG from $29.00 to $21.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Surgery Partners had its price target lowered by Mizuho from $19.00 to $17.00. They now have an “outperform” rating on the stock.
• 3/4/2026 – Surgery Partners had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 3/4/2026 – Surgery Partners had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 3/4/2026 – Surgery Partners had its price target lowered by Royal Bank Of Canada from $31.00 to $20.00. They now have an “outperform” rating on the stock.
• 3/3/2026 – Surgery Partners was given a new $30.00 price target by Jefferies Financial Group Inc..
• 3/3/2026 – Surgery Partners had its “buy” rating reaffirmed by Benchmark Co..
• 3/3/2026 – Surgery Partners had its price target lowered by Barclays PLC from $18.00 to $14.00. They now have an “equal weight” rating on the stock.

Insider Buying and Selling at Surgery Partners

In related news, insider Marissa Brittenham sold 3,657 shares of Surgery Partners stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $12.54, for a total value of $45,858.78. Following the completion of the transaction, the insider owned 94,196 shares in the company, valued at $1,181,217.84. The trade was a 3.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jennifer Baldock sold 5,798 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $13.17, for a total value of $76,359.66. Following the completion of the transaction, the insider directly owned 326,474 shares of the company’s stock, valued at $4,299,662.58. The trade was a 1.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 96,896 shares of company stock worth $1,284,058. 2.70% of the stock is currently owned by company insiders.

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.